Strategic Growth Target medical device distributors and hospital procurement teams with Canady Plasma therapeutic solutions and the Canady Robotic AI Surgical System, highlighting unique post-removal tumor cell targeting that preserves healthy tissue to differentiate from competitors.

Funding Leverage Leverage the recent $11M funding and historical private placements to approach investors and consortiums for co-development, clinical trials, and scaled manufacturing partnerships to accelerate market entry.

Clinical Momentum Capitalize on a track record of plasma-based cancer therapy launches since 2017 and ongoing collaborations with academic institutions to support pilots, case studies, and reimbursement discussions with payers.

Technology Stack Position technology leadership around Canady Plasma and robotic AI surgical capabilities to inform enterprise sales conversations with large hospital networks and donor-advised fund-backed research initiatives seeking cutting-edge solutions.

SMB to Enterprise Given a lean team and mid-market scale, pursue collaborations with mid to large health systems, contract manufacturers, and service integrators to broaden distribution, maintenance support, and training services for rapid adoption.